Weight loss drugs such as Ozempic, Wegovy and Mounjaro seem to directly impact metabolism, not just appetite, according to a new study. It was previously thought these drugs—collectively called glucagon-like peptide 1 (GLP-1) analogs—worked by making people feel fuller so they eat less. But the results of a recent clinical trial suggest it’s not as …
New Delhi: A new analysis found that the profound benefits of Novo Nordisk’s obesity drug Wegovy for people at risk of heart attacks or strokes don’t depend on the number of the scale-cardiovascular health improves whether people lose a lot or even very little weight. That message adds needed nuance to our understanding of the …
Bengaluru: A weekly injection of semaglutide was safe and reduced the amount of fat in the liver by 31 per cent in people with HIV and a type of liver disease, data from a mid-stage study funded by the National Institutes of Health showed. Data from the study was first released on Monday at the …
London: Novo Nordisk’s Ozempic (semaglutide) took the weight loss sector by storm in 2023, propelled by strong efficacy and safety data coupled with social media buzz and celebrity endorsements that elevated the drug to mainstream prominence. However, a potential challenger has emerged in the form of Eli Lilly’s Mounjaro (tirzepatide), which secured FDA approval for …